8,624 Shares in Agilent Technologies, Inc. $A Bought by Voleon Capital Management LP

Key Points

• Voleon Capital Management LP has acquired 8,624 shares of Agilent Technologies, Inc., valued at approximately $1,009,000, marking the firm's new position in the company during the 1st quarter.
• Analysts have mixed ratings for Agilent Technologies, with six analysts giving a Buy rating and six offering a Hold rating, reflecting a current average rating of "Moderate Buy" and an average target price of $139.25.
• CEO Padraig McDonnell sold 1,508 shares of Agilent at an average price of $117.44, decreasing his ownership by 3.87% following the transaction.

Voleon Capital Management LP bought a new position in Agilent Technologies, Inc. (NYSE:A - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 8,624 shares of the medical research company's stock, valued at approximately $1,009,000.

Other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agilent Technologies by 13.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after acquiring an additional 4,362 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after purchasing an additional 2,371 shares during the period. Alps Advisors Inc. increased its holdings in shares of Agilent Technologies by 29.5% during the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after purchasing an additional 3,040 shares during the period. D.A. Davidson & CO. increased its holdings in shares of Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock worth $1,108,000 after purchasing an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. increased its holdings in shares of Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock worth $89,870,000 after purchasing an additional 54,302 shares during the period.

Analyst Ratings Changes

Several research firms have recently issued reports on A. Robert W. Baird boosted their price objective on shares of Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Wall Street Zen downgraded shares of Agilent Technologies from a "buy" rating to a "hold" rating in a report on Friday. Wells Fargo & Company boosted their price objective on shares of Agilent Technologies from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday, August 28th. Evercore ISI dropped their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a report on Thursday, August 28th. Finally, Barclays restated an "equal weight" rating and set a $125.00 price objective on shares of Agilent Technologies in a report on Friday, August 29th. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $139.25.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer directly owned 37,448 shares in the company, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Agilent Technologies Stock Performance

NYSE A opened at $128.13 on Tuesday. The stock has a market cap of $36.32 billion, a P/E ratio of 30.08, a PEG ratio of 4.00 and a beta of 1.24. The company's 50-day simple moving average is $119.42 and its 200 day simple moving average is $116.00. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting analysts' consensus estimates of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm's revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, research analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.